quantisnow
FeedTopReportsPricing
⌘K
Live feed
08:35:41·24d
SECFiling
Tempest Therapeutics Inc. logo

SEC Form 10-K filed by Tempest Therapeutics Inc.

TPST· Tempest Therapeutics Inc.
Health Care
Full content unavailable. See the original source below.
Original source

Companies

  • TPST
    Tempest Therapeutics Inc.
    Health Care

Recent analyst ratings

  • Jan 22UpdateH.C. Wainwright$11.00
  • Apr 10UpdateScotiabank-
  • Apr 10UpdateH.C. Wainwright-
  • Mar 14UpdateScotiabank$13.00
  • Feb 8UpdateJefferies$15.00
  • Oct 21UpdateWilliam Blair-

Related

  • PR1d
    Tempest Announces Key Manufacturing Milestone for TPST-2003 Dual-Targeting CD19/BCMA CAR-T
  • PR9d
    Tempest Appoints Andrew Fang, Ph.D., as Head of Business Development to Advance Strategic Partnerships and Global Licensing Efforts
  • SEC13d
    SEC Form 424B3 filed by Tempest Therapeutics Inc.
  • SEC13d
    SEC Form 424B3 filed by Tempest Therapeutics Inc.
  • SEC14d
    SEC Form EFFECT filed by Tempest Therapeutics Inc.
  • SEC18d
    SEC Form EFFECT filed by Tempest Therapeutics Inc.
  • SEC20d
    SEC Form D filed by Tempest Therapeutics Inc.
  • INSIDER21d
    SEC Form 4 filed by Trojanowski Justin
quantisnow

Real-time market intelligence for retail investors. Press releases, filings, ratings, and insider flow - all in one stream.

All systems operational

Feeds

Press releasesAnalyst ratingsInsider tradingFDASECRSS feeds

Top lists

TrendingBy market capActive companiesAnalyst upgradesInsider purchasesFDA approvalsSEC filingsSectorsMarket reports

Company

AboutPricingPublish with usContact

Legal

Terms of usePrivacy policyCookie policy

© 2026 quantisnow.com · Democratizing insights since 2022